Fig. 3

Results for sensitivity analyses of PS-matched HRs (95% CIs) for respiratory events^‡ associated with the use of SGLT2is versus DPP4is. ^*First case of COVID-19 reported in South Korea. ^†Subdistribution hazards with in-hospital death treated as a competing event. ^‡Defined as a composite end point of acute pulmonary edema, acute respiratory distress syndrome, pneumonia, or respiratory failure. CI, confidence interval; COVID-19, coronavirus disease 2019; DPP4i, dipeptidyl peptidase-4 inhibitors; hHF, hospitalization for heart failure; HR, hazard ratio; PS, propensity score; SGLT2i, sodium-glucose cotransporter 2 inhibitors